Strain "k-58" of avian bursal infectious disease for preparing diagnostic and vaccine preparations

FIELD: veterinary virology, biotechnology.

SUBSTANCE: invention relates to the strain "K-58" that is deposited in the Collection FGU VGNKI at the registration number '"K-58" № 122 - DEP". The strain is reproduced in 9-11-old SPF-chicken embryos with titer value of biological activity 5.5-7.0 lg EID50/0.2 cm3. The strain is stable and harmless. Its attenuation stability is found in carrying out 5 passages in sensitive chickens. The strain shows high biological, immunogenic and antigenic activities in native state and after inactivation and useful for preparing highly specific and sensitive diagnostics and harmless live and inactivated vaccine preparations.

EFFECT: valuable veterinary properties of strain.

7 tbl, 8 ex

 

The invention relates to veterinary Virology and biotechnology and can be used in the manufacture of tools for specific prevention and diagnosis of infectious bursal disease (IBD) birds.

IBD birds (infectious bursitis, disease Gumboro) widespread highly contagious viral disease of chickens, mostly aged 15-80-days, characterized by lesions of fabriciano bags, kidney, intramuscular haemorrhage and diarrhoea.

IBD occurs acutely, with typical clinic disease, and subclinical. Is widespread subclinical form. In the acute form of the disease at the forefront are the clinical and anatomic characteristics peculiar to secondary infections, which creates difficulty in establishing the diagnosis. Therefore, laboratory studies is crucial in the diagnosis and requires a specific high-level standard antigens and sera.

Strains of IBD virus of birds used for the production of antigen and immune serum, should be sufficiently virulent, free from contamination and possess high biological and antigenic activity. Technology of production of the antigen in IBD involves the inactivation of the virus, therefore, the strains must be sensitive to the hcpa is setiu recognized inactivating drugs and controlled on the completeness of inactivation.

IBD birds registered in all countries of the world. In recent years, IBD has become widespread in most large poultry farms in Russia.

The economic damage from IBD caused by the death of chickens up to 20-70% for acute disease, a significant culling of birds, reduced productivity, and as a result of secondary infections, is very large.

Now generally recognized that the only correct and reliable directions in the fight against this infection are timely diagnosis of the disease and its prevention. For specific prophylaxis of IBD using live and inactivated vaccines.

Famous feature of the pathogen IBD is antigenic variability of strains within the same serotype occurring in different time periods and in different territories and dependent species and species composition of bird population, its immune status and many other factors.

In this regard, the choice of vaccine strain virus IBD birds takes into account the antigenic structure of epidemic isolates, and for the preparation of vaccines using production strains possessing the greatest degree of homology in the field of antigenic determinants with epizootic virus isolates IBD (1).

In the fight the Noah practice, the number of known strains of IBD virus of birds, used for the manufacture of diagnostic products for this infection: strain SR-1 (4) and the strain 1/PY". These strains reproduces in SPF chickens (free from pathogenic factors) or in the culture of cells of different origin (2).

However, the replication of the virus in cell culture causes a decrease in its antigenic activity. Samples of antigen and serum obtained from these strains have low antigenic activity and are not amenable to standardization.

In addition, the above strains are unsuitable for use as a vaccine.

Know the use of highly virulent strains of IBD virus of birds for the manufacture of diagnostic kits.

A known strain "cheville", used for the production of antigens and sera for laboratory diagnosis of IBD birds (2). However, this strain is not suitable for the manufacture of vaccines.

Also known strain STB No. 2105 virus IBD birds to obtain diagnostics. Strain reproduce and titrated on a commercial chickens 35-40 days of age, and chicken embryos. The strain causes a characteristic clinical and pathological picture of the disease in 48-72 hours with a titer of virus 5.5 to 6.0 lg EID50/cm3the activity in the serum reaches the neutralization (pH) 1:1024, and in reaction diffusion precipitation (RDP) 1:64. Virus free to the staminali, specific and active (2).

The disadvantage of this strain is its virulence, which always creates problems when the compliance of the veterinary-sanitary regime.

In most cases, the vaccine strains are unsuitable for the manufacture of diagnostic kits because of their low antigenic activity.

A known strain "Winterfeld-2512 virus IBD birds, replicable on 9-11-day-old embryos SPF chickens and used for preparation of vaccines(3, 4, 5).

A known strain BIA 52/70 of IBD virus for the preparation of vaccines, replicable in the tissues of Gabrilovich bags chickens 30-40 days of age or allantoin membranes of chick embryos(6, 7, 8).

A known strain D-78 (ATSS No. VR-2041) virus IBD birds, replicable on 9-11-day-old embryos SPF chickens and used for preparation of vaccines (9).

A known strain GP/82 (NCAJM V(R)-001033) virus IBD birds, replicable in cell cultures of embryonic fibroblasts SPF chickens and used for preparation of vaccines (10).

A known strain "UNIVAP virus IBD birds used for the manufacture of vaccines (11).

A known strain "CPM" virus IBD birds, replicable in transplantable cell cultures buds gray-green monkey VG M-70 and used for preparation of vaccines (12).

A known strain In unterfeld 84" - DEPT virus IBD birds, replicable in a cell culture of fibroblasts of chicken embryos or in 9-11-day-old embryos SPF chickens and used for the manufacture of vaccines (13).

A known strain Bio-92 No. 115 - DEPT virus IBD birds, replicable in cell cultures of chicken embryos or cell cultures of quail embryos and used for the manufacture of diagnostic and vaccine preparations (14).

The General disadvantages of the known strains are low antigenic and immunogenic activity.

Closest to the proposed invention, the essential features is the strain "BG" No. 102 - DEPT virus IBD birds, replicable on 9-11-day-old embryos SPF chickens and used for the manufacture of diagnostic and vaccine preparations (15).

In its antigenic and immunogenic strain "BG" No. 102 - DEPT" surpasses all known strains of IBD virus of birds, of which was prepared by vaccine drugs used on the territory of the Russian Federation and CIS countries(16).

However, the strain-the prototype has a drawback consisting in the fact that it is slightly induces a reduction of the Bursa.

Thus, the problem of search, selection and study of epidemic isolates of the pathogen IBD for new industrial strains of IBD virus in birds with high biological, antigenic and immunogen the th activity in the native form, and after inactivation and suitable for the manufacture of a highly specific and sensitive diagnostic and highly immunogenic and safe vaccines, remains relevant.

In the task of creating the present invention was to obtain a new production strain of IBD virus in birds with high biological, immunogenic and antigenic activity in the native form and after inactivation and suitable for the manufacture of diagnostics and specific prophylaxis of IBD birds.

The technical result from use of the present invention is to expand the Arsenal of strains of IBD virus in birds with high biological, immunogenic and antigenic activity in the native form and after inactivation and suitable for the manufacture of a highly specific and sensitive diagnostic and highly immunogenic and harmless of live and inactivated vaccines.

This technical result is achieved by receiving the attenuated strain "-58" (author's name) virus IBD birds. The strain is new, previously unknown.

The original virus to obtain strain "-58" selected from Gabrilovich bags sick chickens at the poultry farm "Vasilevsky" Penza region in 1994. Production strain "-58" obtained by multiple consecutive pass is the sale of the original isolate in 9-11-day-old embryos SPF chickens and SPF chickens.

Strain K-58" deposited in the all-Russian state collection of strains of microorganisms used in veterinary medicine and animal production, Federal state institution "all-Russian state centre for quality and standardization of veterinary drugs and feed" (FGI VGNKI) of the Ministry of agriculture of the Russian Federation on 1 June 2004 under registration number - strain K-58 NO. 122 - DEPT virus IBD birds.

Compared with the strain of the prototype strain K-58 NO. 122 - DEPT" is harmless and has a higher biological, antigenic and immunogenic activity in the native form and after inactivation. Experimentally confirmed the possibility of its use for the preparation of diagnostic and vaccine preparations.

Strain K-58 NO. 122 - DEPT virus IBD birds characterized by the following features and properties.

Morphological properties

Strain K-58 NO. 122 - DEPT virus IBD bird belongs to the family Birnaviridae, the genus Avibirnavirus, serotype I and has morphological features characteristic of the pathogen IBD: a form of icosahedral virion, the size of the virion 58-60 nm. The capsid T13, the shell is missing.

Antigenic properties

According to their antigenic properties, strain K-58 NO. 122 - DEPOT" refers to serovariants I. the Virus is stable neutralized homologous anticorodal. The virus does not manifest hemagglutinine activity. PR is the vaccine virus induces the formation of specific antibodies, identify the RDP in a dilution of 1:4-1:64, ELISA 1:400-1:10,000 or more, if hyperimmunization in RDP to 1:4096 and above, ELISA>1:10000. When determining antigenic matching vaccine strain K-58 NO. 122 - DEPT" field virus isolates IBD were compared with the variable region of VP2 37 field isolates in 1993-1996 in the territory of the Russian Federation and CIS countries and 7 samples of commercial live vaccines. For this PCR amplified using specific oligonucleotide primers and thermostable Taq DNA polymerase, the variable region of VP2 gene, encoding a major conformational epitope. By direct sequencing determined the nucleotide sequence of this most important manifestation of the antigenic properties of the region of the genome of field isolates and vaccine strains of IBD. It is established that the majority of field isolates of IBD virus, isolated from poultry to Russia, antigenically different from the imported vaccine strains firms "Ron-Marie" (France), "Intervet" (Holland), "Solvay Duphar" (USA), "Safit" (Israel) by 5-8% and have a structure similar to the vaccine strain K-58 NO. 122 - DEPT".

Biotechnological characteristics

Strain K-58 NO. 122 - DEPT" is intended for the manufacture of live and inactivated vaccines and diagnostic Biologicals. Strain K-58 No. 122-DEPT" reproducerea in 9-11-day-old embryos SPF chickens at a temperature of 37.7° C and humidity of 55 and 64%. Within 72-96 hours of incubation the virus accumulates up to 5,5-7,0 lg EID50/0,2 cm3.

Chemo - and geotectonically feature

Strain K-58 NO. 122 - DEPT" is an RNA-containing virus with molmasse RNA 2,16×106Da. Nucleic acid is a 2-thread, 2-segment (a and b). The virus has a protein shell formed with 5 proteins (VP1, VP2, VP3, VP4 and VP5):

VP1 - RNA-dependent RNA polymerase;

VP2, VP3 - structural proteins;

VP4 - protease;

VP5 is not identified.

Lipids are absent.

Strain K-58 NO. 122 - DEPT reveals genetic stability. Most of the mutations are concentrated in the field of RNA that encodes VP2. The mutation leading to the substitution of amino acids determine the antigenic variability of VP2.

Strain K-58 NO. 122 - DEPT" shows a high degree of homology (98%) compared to the numerous group of isolates (30), allocated on the territory of the Russian Federation in 1993-1996,

Physical properties

The mass of the virion is 55,0×106Da. The coefficient of sedimentation devices 460s in sucrose gradient. Floating density of 1.33 to 1.34 g/cm3in the CsCl gradient.

Resistance to external factors

Strain K-58 No. 122-DEPT" resistant to solvents (ether, chloroform) and detergents that are sensitive to formaldehyde, UV-irradiation, γ-radiation and desiccation.

Additional characteristics and properties

The immunogen is gang activity - 100%;

Reactogenicity - no;

Pathogenicity - no;

Virulence - no;

Carcinogenesis - no;

Contagiousness is missing.

Strain K-58 NO. 122 - DEPT is stable and harmless.

The stability of attenuation noted when conducting 5 passages in susceptible chickens.

According to the applicant, the proposed strain meets the conditions of patentability of "novelty" and "inventive step".

The essence of the invention is illustrated by examples of its use.

Example 1

Macrovu virus seed is obtained from strain K-58 NO. 122 - DEPT" on embryos SPF chickens was obtained as follows. On the border Podkolodny shell and chorioallantois shell (HAO) make a notch without damaging HAO, and then with a syringe injected vaccinated material in a quantity 0.2 cm3on HAO. The hole in the shell stick with adhesive tape. Infected embryos incubated at a temperature of 37.7°for 48-120 hours. Dead embryos is cut, frozen at minus 40°S. Vaccinated material is thawed, crushed, extracted at a temperature of 4°C for 45 minutes, twice proparaguay - thawed, add phosphate buffer pH 7.5, centrifuged for 20 minutes at 3000 rpm/min Obtained vaccinated fluid use is as motroway of the seed.

Example 2

Preparation of a diagnostic antigen

SPF-chickens 14-21 days age inoculant virus strain K-58 NO. 122 - DEPT" (intraocular, intranasally or orally). After 72 hours chickens, kill, take Bursa, frozen. Then Bursa finely crushed, rubbed with a sterile glass sand, mixed with phosphate buffer 1:1, twice proparaguay, centrifuged 1 min at 3000 rpm, the supernatant is poured, inactivate and use for work.

Research results in the RDP activity of antigen prepared from strain K-58 NO. 122 - DEPT", are presented in table 1.

Example 3

Preparation of diagnostic serum

SPF - chickens 14-21 days age inoculant oral live vaccine from strain K-58 NO. 122 - DEPT virus IBD. After 14 days intramuscularly inactivated antigen with an oil adjuvant. After two weeks the chickens bleed and receive hyperimmune serum, determining its activity in the RDP and ELISA. Research results serum are presented in tables 2 and 3.

Example 4

Cooking dry diagnostic serum

SPF - chickens 14-21 days of age, type of oral live vaccine from strain K-58 NO. 122 - DEPT virus IBD. After 14 days the Chicks inoculant intramuscular inactivated antigen with an oil adjuvant, within 10 days of the angiogenic drug is administered repeatedly, and in 7 days the chickens bleed, get the serum and determine its activity.

Investigated serum add stabilizing additives and subjected to lyophilization. Liofilizovannye serum used for ELISA test kits and RDP. The research results obtained serum are presented in table 4.

Example 5

Preparation and testing of inactivated vaccines

Inactivated vaccine against IBD birds from strain K-58 NO. 122 - DEPT" prepared from virus grown in the developing embryos SPF chickens as described in example 1.

The virus inactivating aminoethylethanolamine, adsorb to aluminum hydroxide with the addition of saponin.

The results of studies to determine the immunogenic activity of inactivated vaccine from strain K-58 NO. 122 - DEPT" are presented in table 5.

Example 6

Preparation of a live vaccine

At the first stage of preparing matrawy material from strain K-58 NO. 122 - DEPT virus IBD birds as described in example 1. Received vaccinated liquid used for mass infection 9-11-day-old embryos SPF chickens. Viral material in a quantity 0.2 cm3enter on HAO and incubated at a temperature of 37.7°for 48-120 hours. Dead embryos is cut, frozen at minus 40°and received raw materials used in the manufacture of the vaccine. The virus is aderrasi material defrost, ground in a colloid mill, extracted for 45 minutes at a temperature of 4°With double-proparaguay - thawed, add phosphate buffer pH 7.5 and centrifuged for 20 minutes at 3000 rpm Vaccinated supernatant liquid is carefully poured into sterile conditions, and then add the stabilizer, which can be used (separately or in combination) skim milk, lactose, gelatos, sucrose and others, filled into vials, proparaguay at a temperature of minus 60-80°and subjected to lyophilization. Liofilizovannye material sealed under vacuum and subjected to examination for immunogenicity (14-day-old SPF chickens) and emissions (30-day-old SPF chickens).

The resulting vaccine is a dry homogeneous mass of pink-brown color in the form of cylindrical tablets, soluble in water. When dissolved in water to the original volume it turns into a stable homogeneous suspension pink-brown.

The vaccine used in households where recorded clinical and pathological signs of IBD. Chickens Vaccinium with 10-14 days of age with an interval of 10-14 days at a dose of 100-1000 EID50/cm3method of feeding.

Immunity in birds occurs within 14-21 days after the second vaccination and lasts for su is th susceptible to IBD period.

Received the vaccine during the titration in 9-11-day-old SPF chickens has titer 5,5-7,0 lg EID50/0,2 cm3.

Example 7

Test dry live vaccine

The definition of immunogenic vaccines manufactured as described in example 6, was carried out on chickens. This was previously prepared 10-fold dilution of the vaccine and each dilution were immunized 10 chickens by feeding. Immunogenic activity of liofilizovannyh vaccine was evaluated from the results of the control and infected chickens in the experimental and control groups at 14 days after administration of the vaccine. Experiments were performed three times. The research results are summarized in table 6.

Data in table 6 indicate that the diluted 1000 times the vaccine provides 100% protection of chickens, and the feeding of the vaccine with water is an effective way of mass immunization of birds.

Example 8

Comparative evaluation of VirusWall against IBD birds

In laboratory experiments and in the conditions of the poultry farms of the Russian Federation conducted a comparative evaluation of immunogenic activity of domestic and imported live vaccine against IBD and it is shown that virusvaktsinu dry against IBD from strain "BG" No. 102 - DEPT" is a more effective drug in comparison with other domestic and imported drugs. Therefore, the assessment immunogen the th activity of the strain K-58 No. 122 - DEPT conducted in comparison with the strain "BG" No. 102 - DEPT".

The results of the comparative evaluation of immunogenic strain "BG" No. 102 - DEPT and strain K-58 NO. 122 - DEPT" are presented in table 7.

Data in table 7 indicate that the strain C No. 122 - DEPT" is more reliable and efficient, as it is 1.5 times higher than induces antibody titer compared with the strain "BG" No. 102 - DEPT".

Thus, the above information shows the implementation of the use of the present invention, the following cumulative conditions:

- strain K-58 NO. 122 - DEPT virus IBD birds, embodying the invention, intended for use in agriculture, namely in veterinary Virology and biotechnology;

for the present invention in the form as it is described in the independent claim of the invention, confirmed the possibility of its implementation using the steps described in the application or known before the priority date tools and methods;

- strain K-58 No. 122-DEPT virus IBD received in accordance with the invention has, compared with the strain-the prototype of the higher biological, antigenic and immunogenic activity in the native form and after inactivation and expands the Arsenal of strains of IBD virus of birds, suitable for the manufacture of a highly specific and sensitive diagnosis the minds and highly immunogenic and safe vaccines.

Therefore, the present invention meets the condition of patentability "industrial applicability".

Sources of information

1. Syurin NR. and co-authors. Viral diseases of animals. - M.: UNITEMP, 1998, 65-84.

2. Autospid. The USSR №1761802, With 12 N 7/00, 22.11.90,

3. Winterfild R.W. Immunity response to the infectious bursal agent // Avian Dis., 1969, 13, 548-557.

4. Winterfild R.W. et al. Immune response and pathogenecity of different strains of infectious bursal disease virus applied as vaccines // Avian Dis., 1978, 22, 4, 721-731.

5. Winterfild R.W. et al. Characteristics of apparent derivates of the 2512 strain of infectious Bursal Disease virus when used as vaccines // Avian Dis., 1981, 25, 4, 900-910.

6. Wyeth P.F. The veterinary Record, 1979, 104, 188-193.

7. Lucia B et al. Avian Diseases., 1979, 23, 2, 466-478.

8. Pat. Romania No. 100319, a 61 K 39/12, 29.10.90.

9. Pat. U.S. No. 4530831; a 61 K 39/12, With 12 N 7/00, 23.07.85.

10. Pat. Hungary No. 203781; C 12 N 7/00, a 61 K 39/12; 28.08.90.

11. Auth. mon. The USSR №1824443, With 12 N 7/00, 19.03.91.

12. Pat. Of the Russian Federation No. 2205021; a 61 K 39/12, With 12 N 7/00; 27.05.99.

13. Pat. Of the Russian Federation No. 2127604; a 61 K 39/12, With 12 N 7/00; 20.03 99.

14. Pat. Of the Russian Federation No. 2191825; C 12 N 7/00, a 61 K 39/12; 27.10.02.

15. Pat. Of the Russian Federation No. 2127602; a 61 K 39/12, With 12 N 7/00; 20.03.99 (prototype).

16. Scutari I.G. et al. Prevention of infectious diseases of poultry in the Republic of Moldova //veterinary science, 1997, 2, 12-13.

Table 1
Determination of the activity of IBD antigen from strain K-58 No. 122-DEPT" in the RDP
No. desks.Method defined who I activity The activity of antigen
1RDP1:4
2RDP1:4
3RDP1:8
4RDP1:8
5RDP1:8
6RDP1:16
7RDP1:16
8RDP1:16
9RDP1:16
10RDP1:16
Table 2
The determination of the activity of serum
No. of batchesName of productAdjuvantAntibody titer
RDPELISA
1live antigeninact. antigenoil 1:10241:7500
2---1:10241:9100
3---1:10241:10200
4---1:20481:11500
5---1:20481:12300
6---1:20481:12500
7---1:20481:12850

Table 3
The determination of the activity of serum
No. of batchesName of productAdjuvantAntibody titer
RDPELISA
1live antigeninact. antigenoil1:5121:9500
2---1:10241:9750
3---1:10241:10200
4---1:10241:11500
5---1:10241:12080
6---1:20481:12200
7---1:20481:12800
Table 4
Determination of activity of dried whey
No. desks.Name of productAdjuvantAntibody titer
live antigeninactive. antigeninactive. antigen RDPELISA
1---oil1:20481:12500
2----1:20481:13100
3----1:20481:14000
4----1:40961:14500
5----1:40961:15000
6----1:40961:15300
7----1:40961:16100

Table 5
The definition of immunogenic activity of inactivated vaccines is Rotel infectious bursal disease of poultry from strain K-58 No. 122-DEPT"
No. of batchesMaterial nameAntibody titer
RDPELISA
The serum of vaccinated birds1:161:3500
1-1:161:3850
2-1:321:4200
3-1:321:4500
4-1:321:4850
5-1:641:5200
6-1:641:5370
7-1:641:5600
8-1:641:6100
9-1:641:6500
10-1:641:7220
Table 6
Immunogenic activity of VirusWall dry against IBD birds from strain K-58 No. 122-DEPT"
№№ p/pBreeding vaccinesVaccinatedThe results of the control of infection
infectedill% save
The first experience
110-110100100
210-210100100
310-310100100
410-41010190
5Control101010 0
The second experience
110-110100100
210-210100100
310-310100100
410-41010190
5Control1010100
The third experiment
110-110100100
210-210100100
310-310100100
410 -41010190
5Control1010100

Table 7
Comparative evaluation of immunogenicity of the strain "BG" No. 102-DEPT" and "K-58 No. 122-DEPT virus IBD birds
№№ p/pName strains
"BG" No. 102-DEPTK-58 No. 122-DEPT"
Antibody titerAVG. titleAntibody titerAVG. title
11:71771:8872
21:26411:7928
31:54481:5528
41:34441:5779
51:38191:40671:82891:6529
61:21881:8133
7 1:2847
81:43961:7641
91:15381:3338
101:78081:6941

Strain K-58 virus infectious bursal disease of poultry (Bursitis infectiosa gallinae) of the family Birnaviridae, genus Avibirnavirus, serotype 1, a collection of FGI VGNKI "K-58 No. 122-DEPT", for the manufacture of diagnostic and vaccine preparations.



 

Same patents:

FIELD: veterinary virology, veterinary science, biotechnology.

SUBSTANCE: vaccine comprises antigenic material from the strain "VNIIZZH-DEP" of the cattle infectious rhinotracheitis virus reproduced in transplanted cells culture taken among transplanted cells BHK-21, MDBK and ZKG with the biological activity value at least 6.0 lg TCD50/cm3 and inactivated with aminoethylethyleneimine and also aluminum hydroxide as an adjuvant and, additionally, saponin taken in the effective ratios. The strain is deposited in the collection VGNKI at the registration code "VNIIZZH-DEP". Virus of the strain "VNIIZZH-DEP" is reproduced in transplanted cultures of cells BHK-21, MDBK and ZKG inducing cytopathic effect and virus is accumulated with the titer value 6.5-8.0 lg TCD50/cm3 for 48-96 h. Aminoethylethyleneimine is used in the concentration 0.1-0.2%, aluminum hydroxide is used as 3-4% gel in the amount 19.6-49.6 wt.-% and saponin is used as 10% aqueous solution in the amount 0.4 wt.-%. Vaccine shows high antigenic and immunogenic activity and harmless.

EFFECT: valuable properties of vaccine.

18 cl, 8 tbl, 8 ex

FIELD: biotechnology.

SUBSTANCE: claimed strain is obtained by hybridization of epidemic virus with cold adapted and temperature sensitive virus, which represents attenuation donor and is harmless for adults, and infants of 3-14 years old. Said virus makes it possible to obtain reassortant vaccine strains from new epidemic viruses. Strain is effectively cultivated in germinative hen embryos at 32°C, and has temperature sensitivity and cold adaptation. Reassortant has two genes derived from epidemic virus encoding surface proteins (hemagglutinin and neuroamidinase) and six genes derived from attenuation donor encoding non-glycosilated proteins. Strain has no reactogenicity in relation to adults and infants of 3-14 years old at intranasal application.

EFFECT: strain for living influenza intranasal vaccine with good biological properties and reactogenicity.

3 tbl, 2 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: transmissible gastroenteritis of swine virus strain (TGSV) was isolated by sequential passages on SPEV (swine embryo kidney cell) and other cell cultures. Said virus strain is most effectively cultivated in 3-4-day monolayer of SPEV cells, obtained in roll-tube vessel, wherein after cultivation for 24-30 h infective activity level is 7.5 lg TCD50/cm3. Strain survives starting characteristics for 18-month storage and for 9-10 passages (observation time) on SPEV cell culture.

EFFECT: TGSV strain with high biological, antigenic and immunogenic activity useful in production of high-specific and sensitive diagnosticums and high-immunogenic and harmless inactivated vaccine preparations.

7 tbl, 5 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: transmissible gastroenteritis of swine virus strain (TGSV) was isolated by sequential passages on SPEV (swine embryo kidney cell) and other cell cultures. Said virus strain is most effectively cultivated in 3-4-day monolayer of SPEV cells, obtained in roll-tube vessel, wherein after cultivation for 24-30 h infective activity level is 7.5 lg TCD50/cm3. Strain survives starting characteristics for 18-month storage and for 9-10 passages (observation time) on SPEV cell culture.

EFFECT: TGSV strain with high biological, antigenic and immunogenic activity useful in production of high-specific and sensitive diagnosticums and high-immunogenic and harmless inactivated vaccine preparations.

7 tbl, 5 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: transmissible gastroenteritis of swine virus strain (TGSV) was isolated by sequential passages on SPEV (swine embryo kidney cell) and other cell cultures. Said virus strain is most effectively cultivated in 3-4-day monolayer of SPEV cells, obtained in roll-tube vessel, wherein after cultivation for 24-30 h infective activity level is 7.0-8.0 lg TCD50/cm3. Strain survives starting characteristics for 18-month storage and for 9-10 passages (observation time) on SPEV cell culture.

EFFECT: TGSV strain with high biological, antigenic and immunogenic activity useful in production of high-specific and sensitive diagnosticums and high-immunogenic and harmless inactivated vaccine preparations.

7 tbl, 5 ex

FIELD: virology, veterinary science.

SUBSTANCE: invention proposes a new strain of the avian reovirus ESASS № 99011475 belonging to a new antigen class of avian reoviruses. Also, invention proposes a method for preparing such reoviruses, a vaccine comprising such reovirus, a method for its preparing and a method for control against pathological states in poultries by using such vaccine. Proposed group of inventions provides enhancing the effectiveness of vaccination of poultries against reoviruses. Invention can be used in veterinary.

EFFECT: improved preparing method, valuable properties of strain and vaccine.

9 cl, 6 dwg, 3 tbl, 2 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: invention relates to rotavirus strain having high biological, antigenic, and immune activity, as well as dominated properties in relation to epizootic isolates. Claimed virus strain is reproduced in single-layer passed cell cultures wherein after incubation for 24-48 h it accumulates in titer of 5.5-7.5 lg TCD30/cm3. (TCD - tissue cytopathogenic dose). Strain of present invention holds basic biological properties when passing in cell culture.

EFFECT: strain with increased biological, antigenic, and immune activity, inactivation resistance and dominated properties in relation to epizootic isolates.

12 tbl, 5 ex

FIELD: veterinary microbiology, virology, biotechnology.

SUBSTANCE: invention proposes vaccine that comprises as antigens the following components, vol. %: inactivated suspension of cells of hemolytic strains of microorganism M. bovis with the total concentration 100-120 billion cells in 1 cm3: strain M. bovis "G97-VNIVI", 4.0-5.0; strain M. bovis "SHZ-01", 4.0-5.0; inactivated cultural suspension of the strain Herpesvirus bovis type I "TKA-VIEV-V2" with infectious titer 107.0 - 107.5 TCD50/ml, 78.0-83.0; 6% solution of aluminum hydroxide gel, the balance. Vaccine enhances accumulation of specific protective antibodies in serum blood of vaccinated animals and provides the development of immunity against infectious keratoconjunctivitis that is retained for one year.

EFFECT: enhanced effectiveness and valuable properties of vaccine.

4 tbl, 6 ex

FIELD: medicine, genetic engineering.

SUBSTANCE: invention proposes a method that involves construction of bacteriophage library of random peptides based on oligonuleotide fragments encoding their, selection of bacteriophages binding with target-cells but not binding with cells of other types that can be involves in pathological process or able to show effect on its diagnosis and therapy, and confirmation of specificity of selected bacteriophages by using combination of different tests. Oligonucleotide fragments encoding random peptides are prepared by reaction of reverse transcription by using random primers and total RNAs isolated from indicated target-cells and cells of other types. Applying this invention provides preparing bacteriophages binding with target-cells with high degree of selectivity. Invention can be used in diagnosis, therapy and pharmaceutical industry.

EFFECT: improved preparing method.

3 cl, 2 dwg, 8 ex

FIELD: virology.

SUBSTANCE: invention proposes the strain CoD of severe acute respiratory syndrome virus. The strain is isolated from a nasopharynx washing off eluate taken of in a patient. The strain is deposited in the Specialized collection of virus in Virological center NII microbiology of Russian Federation the Defense Ministry at № 1136. The proposed strain is the first isolated strain of coronavirus of IV genotype in Russian Federation region. The strain possesses biological activity in cells Vero E6 = 7.1 lg CPD50 x cm-3. The proposed strain can be used as diagnosticum in IFA-system for determination of antibodies raised against the severe acute respiratory syndrome virus in human blood. Also, the strain can be used as a positive control specimen in PCR-test-system for detection of severe acute respiratory syndrome virus RNA.

EFFECT: valuable properties of virus.

1 dwg, 1 tbl

FIELD: veterinary virology, veterinary science, biotechnology.

SUBSTANCE: vaccine comprises antigenic material from the strain "VNIIZZH-DEP" of the cattle infectious rhinotracheitis virus reproduced in transplanted cells culture taken among transplanted cells BHK-21, MDBK and ZKG with the biological activity value at least 6.0 lg TCD50/cm3 and inactivated with aminoethylethyleneimine and also aluminum hydroxide as an adjuvant and, additionally, saponin taken in the effective ratios. The strain is deposited in the collection VGNKI at the registration code "VNIIZZH-DEP". Virus of the strain "VNIIZZH-DEP" is reproduced in transplanted cultures of cells BHK-21, MDBK and ZKG inducing cytopathic effect and virus is accumulated with the titer value 6.5-8.0 lg TCD50/cm3 for 48-96 h. Aminoethylethyleneimine is used in the concentration 0.1-0.2%, aluminum hydroxide is used as 3-4% gel in the amount 19.6-49.6 wt.-% and saponin is used as 10% aqueous solution in the amount 0.4 wt.-%. Vaccine shows high antigenic and immunogenic activity and harmless.

EFFECT: valuable properties of vaccine.

18 cl, 8 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vestibular and auditory disorders, trigeminal nerve's neuralgia and peripheral paresis of facial nerve of herpetic etiology. The method deals with introduction of an antiherpetic preparation followed by immunomodelling therapy with the use of polyoxidonium. Moreover, after treating with antiherpetic preparation before introducing polyoxidonium it is necessary to conduct additional successive therapy: with preparations of trophic action as milgamma or neuromultivit at simultaneous introduction of antioxidant, then comes intratissue injection of cerebrolysine being behind the top of mastoid process.

EFFECT: the innovation enables to decrease the quantity of relapses due to stopping the development of herpes simplex virus, restore conductivity along nervous fiber and improve endoneural circulation.

3 cl, 3 ex

Medicinal agent // 2268037

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to using 4-chloro-2-methylphenoxyacetic acid of the formula (I)

and its pharmacologically acceptable sodium, potassium and lithium salts (mixture of these salts, or mixture of salts and 4-chloro-2-methylphenoxyacetic acid) as a medicinal agent possessing immunomodulating, anti-inflammatory and antitumor properties, and antiviral activity also. 4-Chloro-2-methylphenoxyacetic acid and its mixtures with pharmacologically acceptable alkaline metal salts possess high effectiveness and enhanced bioavailability.

EFFECT: valuable medicinal properties of medicinal agent.

9 cl, 13 ex

FIELD: chemistry of peptides, medicine.

SUBSTANCE: invention relates to preparing new peptides possessing immunomodulating, anti-proliferative, anti-tumor and antiviral activity. Invention proposes new peptides comprising up to 30 amino acid residues of the general structural formula: X1-Trp-Gly-Gln-X2 wherein X1 is taken among the following group: -His-Gly-Val-Ser-Gly-, -His-Gly-Gly-Gly-, -His-Val-Gly-Gly-, -His-Gly-Gly-Gly-Gly-, and -Gln-Gly-Gly-Gly-Gly, or absent; X2 is taken among the following group: -His-Gly-Thr-His-Gly, -Gly-Gly-Thr-His-Gly, -Pro-His-Val-Gly-Gly, -Pro-His-Gly-Gly-Gly, -Pro-His-Gly-Gly-Gly-Trp-Gly, -Gly-Gly-Gly-Thr-His-Ser, or absent.

EFFECT: valuable medicinal properties of peptides.

8 cl, 5 tbl, 5 dwg, 6 ex

FIELD: organic chemistry, medicine, virology.

SUBSTANCE: invention relates to new derivatives of piperidine of the general formula (II): or their pharmaceutically acceptable salts wherein Xa means -C(R13)2-, -C(R13)(R19)-, -C(O)-, and others; Ra means R6a-phenyl or phenyl substituted with methylsulfonyl; R1 means hydrogen atom or (C1-C6)-alkyl; R2 means R7-, R8-, R9-phenyl wherein R7-, R8 and R9 mean substituted 6-membered heteroaryl and others; R3 means R10-phenyl, pyridyl and others; R4 means hydrogen atom, (C1-C6)-alkyl, fluoro-(C1-C6)-alkyl; R6a means from 1 to 3 substitutes taken among the group involving hydrogen, halogen atom, -CF3 and CF3O-; R7 and R8 mean (C1-C6)-alkyl and others; R9 means R7, hydrogen atom, phenyl and others; R10 means (C1-C6)-alkyl, -NH2 or R12-phenyl wherein R12 means hydrogen atom, (C1-C6)-alkyl and others; R13, R14, R15 and R16 mean hydrogen atom or (C1-C6)-alkyl; R17 and R18 in common with carbon atom to which they are bound form spirane ring comprising from 3 to 6 carbon atoms; R19 means R6-phenyl wherein R6 means R6a or methylsulfonyl; R20, R21 and R22 mean hydrogen atom or (C1-C6)-alkyl; R23 means (C1-C6)-alkyl under condition that if Ra means phenyl substituted with methylsulfonyl then Xa can mean the group only. Compounds of the formula (II) possess properties of CCR5-antagonist and can be used in medicine in treatment of HIV-infection.

EFFECT: improved method for treatment, valuable medicinal properties of compounds and composition.

15 cl, 1 dwg, 12 tbl, 15 ex

FIELD: virology, veterinary science.

SUBSTANCE: invention proposes a new strain of the avian reovirus ESASS № 99011475 belonging to a new antigen class of avian reoviruses. Also, invention proposes a method for preparing such reoviruses, a vaccine comprising such reovirus, a method for its preparing and a method for control against pathological states in poultries by using such vaccine. Proposed group of inventions provides enhancing the effectiveness of vaccination of poultries against reoviruses. Invention can be used in veterinary.

EFFECT: improved preparing method, valuable properties of strain and vaccine.

9 cl, 6 dwg, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: one should perform the following stages: a) removal of contaminants out of plant; b) plant's reducing; c) treatment of reduced plant with laser radiation; d) suspending the mixture obtained at stage c) in water; e) maceration of suspension obtained at stage d) and f) separation of liquid developed. Composition should be obtained due to this technique. It should be applied at treating hepatitis C as an aqueous extract. It should be applied as aqueous extract as immunostimulant. Pharmaceutical preparation includes aqueous extract as an active constituent.

EFFECT: increased biological activity of the product.

43 cl, 16 ex, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new urea-substituted imidazoquinolines of the formula (1):

wherein R, R1, R2 and n have values given in the description, and to pharmaceutical preparations based on these compounds. Proposed compounds possess effect of immunomodulators initiating biosynthesis of different cytokines. Also, invention relates to methods for treatment of different states, among them viral diseases and neoplastic pathologies.

EFFECT: improved method for induction, valuable properties of compounds.

47 cl, 11 tbl, 142 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with applying birch bark extract at betulin content in it being above 70% for the purpose to prevent viral hepatitis C and, moreover, manufacture medicinal preparation for preventing viral hepatitis C.

EFFECT: higher efficiency of prophylaxis.

2 cl, 1 tbl

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes preparation that comprises the immunoelectrophoretically pure secretory immunoglobulin A isolated from whey milk and/or colostrum of immunized ungulate animals and pharmaceutically acceptable vehicles. The base preparation (substance) comprises 6-12% of secretory immunoglobulin A at pH 4-8, an anti-complementary activity at least 10 mg of protein, not activating 2 CH50, protects in >70% against corresponding infections (in infection macroorganism in doses ≥10 ID50), shows areactogenic property in intravenous administration, can comprise stabilizing additives in the total concentration 4%, not above. The preparation possesses high purity, low anti-complementary activity, stable in storage, useful for oral, parenteral and topical using and possesses therapeutic activity with respect to microorganisms and viruses against which humans and animals immunization have been carried out. Invention can be used in treatment and prophylaxis of immunodeficiency states, bacterial and viral infections in humans and animals.

EFFECT: valuable medicinal and veterinary properties of preparation.

9 cl, 1 tbl, 10 ex

Viral vaccine // 2268067

FIELD: medicine.

SUBSTANCE: invention relates to viral vaccines, in particular, to viral vaccines representing viral antigen or vaccine preparation mixed with the immunogenic composition comprising beta-carotene, mannitol, polyvinylpyrrolidone and polyoxydonium wherein the content of polyoxydonium is 0.04-12 mg per a dose. Proposed viral vaccines are used against hepatitis A, hepatitis B, hepatitis A and B and rabies. Invention provides enhancing immunogenicity of vaccine.

EFFECT: improved and valuable properties of vaccines.

12 cl, 6 tbl, 6 ex

Up!